Úloha mimotělní membránové oxygenace v léčbě syndromu mekoniové aspirace

Translated title of the contribution: Role of Extracorporeal Membrane Oxygenation in the Treatment of Meconium Aspiration Syndrome

J. Podzimková, Giles J. Peek, Z. Slavík, A. Sosnowski, H. M. Moore, N. A. Moore, R. Leanage, K. C. Chan, R. K. Firmin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

More experience is required with the assessment of recently developed therapeutic methods for neonates with respiratory failure. Meconium aspiration syndrome (MAS) remains the most frequent cause of severe neonatal respiratory failure. We reviewed the experience with extracorporeal membrane oxygenation (ECMO) in MAS in a centre specializing in ECMO treatment. Between August 1989 and October 1996, 126 neonates underwent ECMO for severe respiratory failure in one institution. Forty one of these (33 %) presented with MAS at a median age of 24 hours (range 5 - 168 hours). The duration of ECMO treatment ranged from 45 to 250 hours (median 87 hours). Forty patients (97.6 %) survived ECMO and were transferred to referring hospitals. In 1 case, ECMO treatment was terminated for severe ischaemic brain injury. Mortality in MAS treated with ECMO (2.4 %) compares favourably with overall mortality (34.5 %) of other neonates undergoing ECMO for respiratory failure. Patients with MAS were younger (41 ± 38 hours, mean ± SD) at the time of referral and their course on ECMO shorter (93 ± 40 hours) than in the remaining neonates (86 ± 105 hours, p = 0,0008, and 158 ± 118 hours, p < 0.0001, respectively). The 10 patients with MAS who required venoarterial ECMO due to concomitant cardiac failure did not differ from the remaining 31 neonates undergoing venovenous ECMO as to their age, weight, and oxygenation index at presentation nor as to the period on ECMO (86 ± 29 hours v. 96 ± 43 hours, p = 0.43). We conclude that ECMO is a safe alternative to other methods of treatment in neonates with severe MAS. Early referral for ECMO in patients with MAS who do not respond favourably to conventional treatment is desirable.

Original languageCzech
Pages (from-to)175-179
Number of pages5
JournalCesko-Slovenska Pediatrie
Volume52
Issue number4
StatePublished - 1997
Externally publishedYes

Fingerprint

Meconium Aspiration Syndrome
Extracorporeal Membrane Oxygenation
Newborn Infant
Respiratory Insufficiency
Therapeutics
Referral and Consultation
Mortality

Keywords

  • Extracorporeal membrane oxygenation
  • Meconium aspiration
  • Newborn
  • Respiratory failure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Podzimková, J., Peek, G. J., Slavík, Z., Sosnowski, A., Moore, H. M., Moore, N. A., ... Firmin, R. K. (1997). Úloha mimotělní membránové oxygenace v léčbě syndromu mekoniové aspirace. Cesko-Slovenska Pediatrie, 52(4), 175-179.

Úloha mimotělní membránové oxygenace v léčbě syndromu mekoniové aspirace. / Podzimková, J.; Peek, Giles J.; Slavík, Z.; Sosnowski, A.; Moore, H. M.; Moore, N. A.; Leanage, R.; Chan, K. C.; Firmin, R. K.

In: Cesko-Slovenska Pediatrie, Vol. 52, No. 4, 1997, p. 175-179.

Research output: Contribution to journalArticle

Podzimková, J, Peek, GJ, Slavík, Z, Sosnowski, A, Moore, HM, Moore, NA, Leanage, R, Chan, KC & Firmin, RK 1997, 'Úloha mimotělní membránové oxygenace v léčbě syndromu mekoniové aspirace', Cesko-Slovenska Pediatrie, vol. 52, no. 4, pp. 175-179.
Podzimková J, Peek GJ, Slavík Z, Sosnowski A, Moore HM, Moore NA et al. Úloha mimotělní membránové oxygenace v léčbě syndromu mekoniové aspirace. Cesko-Slovenska Pediatrie. 1997;52(4):175-179.
Podzimková, J. ; Peek, Giles J. ; Slavík, Z. ; Sosnowski, A. ; Moore, H. M. ; Moore, N. A. ; Leanage, R. ; Chan, K. C. ; Firmin, R. K. / Úloha mimotělní membránové oxygenace v léčbě syndromu mekoniové aspirace. In: Cesko-Slovenska Pediatrie. 1997 ; Vol. 52, No. 4. pp. 175-179.
@article{3de5814a137e4f5e99d56f8ab4c530e1,
title = "{\'U}loha mimotěln{\'i} membr{\'a}nov{\'e} oxygenace v l{\'e}čbě syndromu mekoniov{\'e} aspirace",
abstract = "More experience is required with the assessment of recently developed therapeutic methods for neonates with respiratory failure. Meconium aspiration syndrome (MAS) remains the most frequent cause of severe neonatal respiratory failure. We reviewed the experience with extracorporeal membrane oxygenation (ECMO) in MAS in a centre specializing in ECMO treatment. Between August 1989 and October 1996, 126 neonates underwent ECMO for severe respiratory failure in one institution. Forty one of these (33 {\%}) presented with MAS at a median age of 24 hours (range 5 - 168 hours). The duration of ECMO treatment ranged from 45 to 250 hours (median 87 hours). Forty patients (97.6 {\%}) survived ECMO and were transferred to referring hospitals. In 1 case, ECMO treatment was terminated for severe ischaemic brain injury. Mortality in MAS treated with ECMO (2.4 {\%}) compares favourably with overall mortality (34.5 {\%}) of other neonates undergoing ECMO for respiratory failure. Patients with MAS were younger (41 ± 38 hours, mean ± SD) at the time of referral and their course on ECMO shorter (93 ± 40 hours) than in the remaining neonates (86 ± 105 hours, p = 0,0008, and 158 ± 118 hours, p < 0.0001, respectively). The 10 patients with MAS who required venoarterial ECMO due to concomitant cardiac failure did not differ from the remaining 31 neonates undergoing venovenous ECMO as to their age, weight, and oxygenation index at presentation nor as to the period on ECMO (86 ± 29 hours v. 96 ± 43 hours, p = 0.43). We conclude that ECMO is a safe alternative to other methods of treatment in neonates with severe MAS. Early referral for ECMO in patients with MAS who do not respond favourably to conventional treatment is desirable.",
keywords = "Extracorporeal membrane oxygenation, Meconium aspiration, Newborn, Respiratory failure",
author = "J. Podzimkov{\'a} and Peek, {Giles J.} and Z. Slav{\'i}k and A. Sosnowski and Moore, {H. M.} and Moore, {N. A.} and R. Leanage and Chan, {K. C.} and Firmin, {R. K.}",
year = "1997",
language = "Czech",
volume = "52",
pages = "175--179",
journal = "Cesko-Slovenska Pediatrie",
issn = "0069-2328",
publisher = "Czech Medical Association J.E. Purkyne",
number = "4",

}

TY - JOUR

T1 - Úloha mimotělní membránové oxygenace v léčbě syndromu mekoniové aspirace

AU - Podzimková, J.

AU - Peek, Giles J.

AU - Slavík, Z.

AU - Sosnowski, A.

AU - Moore, H. M.

AU - Moore, N. A.

AU - Leanage, R.

AU - Chan, K. C.

AU - Firmin, R. K.

PY - 1997

Y1 - 1997

N2 - More experience is required with the assessment of recently developed therapeutic methods for neonates with respiratory failure. Meconium aspiration syndrome (MAS) remains the most frequent cause of severe neonatal respiratory failure. We reviewed the experience with extracorporeal membrane oxygenation (ECMO) in MAS in a centre specializing in ECMO treatment. Between August 1989 and October 1996, 126 neonates underwent ECMO for severe respiratory failure in one institution. Forty one of these (33 %) presented with MAS at a median age of 24 hours (range 5 - 168 hours). The duration of ECMO treatment ranged from 45 to 250 hours (median 87 hours). Forty patients (97.6 %) survived ECMO and were transferred to referring hospitals. In 1 case, ECMO treatment was terminated for severe ischaemic brain injury. Mortality in MAS treated with ECMO (2.4 %) compares favourably with overall mortality (34.5 %) of other neonates undergoing ECMO for respiratory failure. Patients with MAS were younger (41 ± 38 hours, mean ± SD) at the time of referral and their course on ECMO shorter (93 ± 40 hours) than in the remaining neonates (86 ± 105 hours, p = 0,0008, and 158 ± 118 hours, p < 0.0001, respectively). The 10 patients with MAS who required venoarterial ECMO due to concomitant cardiac failure did not differ from the remaining 31 neonates undergoing venovenous ECMO as to their age, weight, and oxygenation index at presentation nor as to the period on ECMO (86 ± 29 hours v. 96 ± 43 hours, p = 0.43). We conclude that ECMO is a safe alternative to other methods of treatment in neonates with severe MAS. Early referral for ECMO in patients with MAS who do not respond favourably to conventional treatment is desirable.

AB - More experience is required with the assessment of recently developed therapeutic methods for neonates with respiratory failure. Meconium aspiration syndrome (MAS) remains the most frequent cause of severe neonatal respiratory failure. We reviewed the experience with extracorporeal membrane oxygenation (ECMO) in MAS in a centre specializing in ECMO treatment. Between August 1989 and October 1996, 126 neonates underwent ECMO for severe respiratory failure in one institution. Forty one of these (33 %) presented with MAS at a median age of 24 hours (range 5 - 168 hours). The duration of ECMO treatment ranged from 45 to 250 hours (median 87 hours). Forty patients (97.6 %) survived ECMO and were transferred to referring hospitals. In 1 case, ECMO treatment was terminated for severe ischaemic brain injury. Mortality in MAS treated with ECMO (2.4 %) compares favourably with overall mortality (34.5 %) of other neonates undergoing ECMO for respiratory failure. Patients with MAS were younger (41 ± 38 hours, mean ± SD) at the time of referral and their course on ECMO shorter (93 ± 40 hours) than in the remaining neonates (86 ± 105 hours, p = 0,0008, and 158 ± 118 hours, p < 0.0001, respectively). The 10 patients with MAS who required venoarterial ECMO due to concomitant cardiac failure did not differ from the remaining 31 neonates undergoing venovenous ECMO as to their age, weight, and oxygenation index at presentation nor as to the period on ECMO (86 ± 29 hours v. 96 ± 43 hours, p = 0.43). We conclude that ECMO is a safe alternative to other methods of treatment in neonates with severe MAS. Early referral for ECMO in patients with MAS who do not respond favourably to conventional treatment is desirable.

KW - Extracorporeal membrane oxygenation

KW - Meconium aspiration

KW - Newborn

KW - Respiratory failure

UR - http://www.scopus.com/inward/record.url?scp=2442526871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442526871&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:2442526871

VL - 52

SP - 175

EP - 179

JO - Cesko-Slovenska Pediatrie

JF - Cesko-Slovenska Pediatrie

SN - 0069-2328

IS - 4

ER -